Abstract
Neurologic and myopathic complications are a frequent cause of morbidity in the post transplant (Tx) clinical course. Myopathic discomfort and muscular weakness are known to be related to the use of calcineurininhibitors (CNIs). So far these side effects had to be tolerated due to lack of alternatives to CNIs. The emergence of proliferation signal inhibitors (PSIs) as novel immunosuppressive agents might allow for a change of the maintenance immunosuppressive regimen to avoid disabling CNI-associated myopathy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Paper Title
Journal
Date
